These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22248133)

  • 41. Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease.
    Benincasa D; Pellicano C; Fanciulli A; Pontieri FE
    Mov Disord; 2011 Feb; 26(2):355-7. PubMed ID: 21412840
    [No Abstract]   [Full Text] [Related]  

  • 42. Medication-related impulse control and repetitive behaviors in Parkinson disease.
    Voon V; Fox SH
    Arch Neurol; 2007 Aug; 64(8):1089-96. PubMed ID: 17698698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
    Wedekind S
    MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622
    [No Abstract]   [Full Text] [Related]  

  • 44. Clozapine prevents recurrence of psychosis in Parkinson's disease.
    Factor SA; Brown D
    Mov Disord; 1992; 7(2):125-31. PubMed ID: 1350059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence.
    Tarrants ML; Denarié MF; Castelli-Haley J; Millard J; Zhang D
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):374-83. PubMed ID: 20869623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 47. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
    Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A
    Adv Neurol; 1996; 69():545-50. PubMed ID: 8615179
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacotherapy for Parkinson's disease: current options, promising future therapies.
    Moser SS; Besler-Panos W
    JAAPA; 2006 Aug; 19(8):38-44. PubMed ID: 16918085
    [No Abstract]   [Full Text] [Related]  

  • 49. Pathological gambling in Parkinson's disease: disease related or drug related?
    Calandrella D; Antonini A
    Expert Rev Neurother; 2011 Jun; 11(6):809-14. PubMed ID: 21651329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Between Scylla and Charybdis: drug-induced psychosis in patients with Parkinson disease].
    Kuiper MA; Zwaan WA; Wolters EC
    Ned Tijdschr Geneeskd; 1994 Jul; 138(27):1353-7. PubMed ID: 8035892
    [No Abstract]   [Full Text] [Related]  

  • 51. Hallucinations in Parkinson's disease: the clinical syndrome.
    Goetz CG
    Adv Neurol; 1999; 80():419-23. PubMed ID: 10410750
    [No Abstract]   [Full Text] [Related]  

  • 52. L-dopa treatment duration versus Parkinson's disease progression: the dorsal-ventral divide.
    Belujon P; Grace AA
    Mov Disord; 2013 Feb; 28(2):120-1. PubMed ID: 23401218
    [No Abstract]   [Full Text] [Related]  

  • 53. Text messaging as a new compulsive behavior in a patient with Parkinson's disease.
    Ertem DH; Maner F; Koksal A
    Psychiatry Clin Neurosci; 2013 Feb; 67(2):126-7. PubMed ID: 23438166
    [No Abstract]   [Full Text] [Related]  

  • 54. The thrill of reckless driving in patients with Parkinson's disease: an additional behavioural phenomenon in dopamine dysregulation syndrome?
    Avanzi M; Baratti M; Cabrini S; Uber E; Brighetti G; Bonfà F
    Parkinsonism Relat Disord; 2008; 14(3):257-8. PubMed ID: 17561433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Addictions, drives and Parkinson's disease].
    Azulay JP
    Rev Neurol (Paris); 2008 Apr; 164(4):308-9. PubMed ID: 18439922
    [No Abstract]   [Full Text] [Related]  

  • 56. Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders.
    Ceravolo R; Frosini D; Rossi C; Bonuccelli U
    J Neurol; 2010 Nov; 257(Suppl 2):S276-83. PubMed ID: 21080189
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopaminergic psychosis in advanced Parkinson's disease.
    Fischer P; Danielczyk W; Simanyi M; Streifler MB
    Adv Neurol; 1990; 53():391-7. PubMed ID: 2122647
    [No Abstract]   [Full Text] [Related]  

  • 58. "Silly walks" in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias.
    Růžička E; Zárubová K; Nutt JG; Bloem BR
    Mov Disord; 2011 Aug; 26(9):1782-4. PubMed ID: 21495073
    [No Abstract]   [Full Text] [Related]  

  • 59. Low frequency of bipolar disorder, dopamine dysregulation syndrome, and punding in Brazilian patients with Parkinson's disease.
    Kummer A; Dias FM; Cardoso F; Teixeira AL
    Braz J Psychiatry; 2010 Mar; 32(1):62-5. PubMed ID: 20339736
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
    Harvey NS
    Psychosomatics; 1986 Mar; 27(3):175-7, 180, 181-4. PubMed ID: 2870536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.